Schein outpaces Q3 earnings estimates but dampens full-year forecast

Despite a 3% decline in its animal-health revenues, distributor Henry Schein ($HSIC) turned in a better-than-expected third quarter. Schein reported sales of $2.7 billion and adjusted earnings of $130.6 million, or $1.55 per share, well above the Zacks consensus estimate of $1.46. But unfavorable currency exchange rates continue to hamper results. The company lowered the high end of its expected full-year EPS, from $6 per share to $5.96. CEO Stanley Bergman said he anticipates that the recent acquisitions of Kruuse and Vetstreet will help fuel growth in animal health. Release

Suggested Articles

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

After two years of implementing an across-the-board efficiency plan, fine-tuning its product portfolio and getting manufacturing up to speed on Apoquel, animal…